title: Mechanism of inhibition of MMTV-neu and MMTV-wnt1 induced mammary oncogenesis by RARalpha agonist AM580.
abstract: We hypothesized that specific activation of a single retinoic acid receptor-alpha (RARalpha), without direct and concurrent activation of RARbeta and gamma, will inhibit mammary tumor oncogenesis in murine models relevant to human cancer. A total of 50 uniparous mouse mammary tumor virus (MMTV)-neu and 50 nuliparous MMTV-wnt1 transgenic mice were treated with RARalpha agonist (retinobenzoic acid, Am580) that was added to the diet for 40 (neu) and 35 weeks (wnt1), respectively. Among the shared antitumor effects was the inhibition of epithelial hyperplasia, a significant increase (P<0.05) in tumor-free survival and a reduction in tumor incidence and in the growth of established tumors. In both models, the mechanisms responsible for these effects involved inhibition of proliferation and survival pathways, and induction of apoptosis. The treatment was more effective in the MMTV-wnt1 model in which Am580 also induced differentiation, in both in vivo and three-dimensional (3D) cultures. In these tumors Am580 inhibited the wnt pathway, measured by loss of nuclear beta-catenin, suggesting partial oncogene dependence of therapy. Am580 treatment increased RARbeta and lowered the level of RARgamma, an isotype whose expression we linked with tumor proliferation. The anticancer effect of RARalpha, together with the newly discovered pro-proliferative role of RARgamma, suggests that specific activation of RARalpha and inhibition of RARgamma might be effective in breast cancer therapy.
authors.affiliation: Division of Hematology-Oncology, Department of Medicine, Tisch Cancer Center, Mount Sinai School of Medicine, New York, NY, USA.
authors.forename: Y
authors.initials: Y
authors.lastname: Lu
authors.forename: S
authors.initials: S
authors.lastname: Bertran
authors.forename: T-A
authors.initials: TA
authors.lastname: Samuels
authors.forename: R
authors.initials: R
authors.lastname: Mira-y-Lopez
authors.forename: E F
authors.initials: EF
authors.lastname: Farias
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D001565:Benzoates / Q000494:pharmacology* / Q000627:therapeutic use; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D002472:Cell Transformation, Viral / Q000235:genetics; D005260:Female; D006801:Humans; D008325:Mammary Neoplasms, Experimental / Q000188:drug therapy / Q000473:pathology* / Q000821:virology; D008324:Mammary Tumor Virus, Mouse / Q000235:genetics* / Q000502:physiology*; D051379:Mice; D008822:Mice, Transgenic; D009857:Oncogenes / Q000235:genetics; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics*; D018168:Receptors, Retinoic Acid / Q000819:agonists*; D000072482:Retinoic Acid Receptor alpha; D013764:Tetrahydronaphthalenes / Q000494:pharmacology* / Q000627:therapeutic use; D051155:Wnt1 Protein / Q000235:genetics*
chemical_list: D000970:Antineoplastic Agents; D001565:Benzoates; D018719:Erb-b2 Receptor Tyrosine Kinases; D018168:Receptors, Retinoic Acid; D000072482:Retinoic Acid Receptor alpha; D013764:Tetrahydronaphthalenes; D051155:Wnt1 Protein; C000607071:RARA protein, human; C000607072:Rara protein, mouse; C068073:Am 580
references.citation: Nat Cell Biol. 2001 Sep;3(9):793-801
references.pmid: 11533658
references.citation: Cell. 2006 Nov 3;127(3):469-80
references.pmid: 17081971
references.citation: J Biol Chem. 1997 Jul 25;272(30):18538-41
references.pmid: 9228017
references.citation: N Engl J Med. 1993 Jul 15;329(3):177-89
references.pmid: 8515790
references.citation: Curr Opin Hematol. 2008 Jul;15(4):346-51
references.pmid: 18536573
references.citation: Cancer Invest. 2003 Apr;21(2):304-12
references.pmid: 12743994
references.citation: J Natl Cancer Inst. 1995 Nov 15;87(22):1655-7
references.pmid: 7473809
references.citation: J Biol Chem. 2002 Jul 12;277(28):24859-62
references.pmid: 12032135
references.citation: Genes Dev. 2000 Aug 1;14(15):1837-51
references.pmid: 10921899
references.citation: Br J Cancer. 2001 Aug 17;85(4):630-5
references.pmid: 11506507
references.citation: Science. 2004 Mar 5;303(5663):1483-7
references.pmid: 15001769
references.citation: EMBO J. 2002 Jul 1;21(13):3402-13
references.pmid: 12093741
references.citation: Mol Cell Biol. 2001 Feb;21(3):893-901
references.pmid: 11154276
references.citation: J Mammary Gland Biol Neoplasia. 2004 Apr;9(2):119-31
references.pmid: 15300008
references.citation: Cell. 2007 Jun 15;129(6):1097-110
references.pmid: 17574023
references.citation: Biochem Pharmacol. 2008 Mar 1;75(5):1129-60
references.pmid: 18164278
references.citation: J Med Chem. 1988 Nov;31(11):2182-92
references.pmid: 3184125
references.citation: Science. 1987 Jan 9;235(4785):177-82
references.pmid: 3798106
references.citation: PPAR Res. 2007;2007:73256
references.pmid: 18274629
references.citation: J Exp Med. 1925 Nov 30;42(6):753-77
references.pmid: 19869087
references.citation: Mol Pharmacol. 1991 Oct;40(4):556-62
references.pmid: 1656191
references.citation: Cancer Res. 2000 Oct 1;60(19):5479-87
references.pmid: 11034091
references.citation: Mol Pharmacol. 2005 May;67(5):1808-17
references.pmid: 15703382
references.citation: Fed Proc. 1976 May 1;35(6):1332-8
references.pmid: 770206
references.citation: Cell. 1988 Jul 1;54(1):105-15
references.pmid: 2898299
references.citation: Mol Cancer. 2008 Nov 06;7:83
references.pmid: 18990230
references.citation: Br J Cancer. 1998;77(1):26-32
references.pmid: 9459142
references.citation: J Clin Oncol. 2001 Jun 15;19(12):3010-7
references.pmid: 11408495
references.citation: Curr Biol. 1999 Dec 2;9(23):1415-8
references.pmid: 10607566
references.citation: Gene. 2000 Apr 18;247(1-2):1-15
references.pmid: 10773440
references.citation: Methods. 2003 Jul;30(3):256-68
references.pmid: 12798140
references.citation: J Exp Med. 2006 May 15;203(5):1283-93
references.pmid: 16682494
references.citation: Breast Cancer Res. 2008;10(5):R82
references.pmid: 18826564
references.citation: Endocr Rev. 2005 Dec;26(7):898-915
references.pmid: 16126938
references.citation: Methods Enzymol. 1990;190:395-406
references.pmid: 2087191
references.citation: Nutr Rev. 1978 Jan;36(1):16-9
references.pmid: 342996
references.citation: Nutr Rev. 2000 Jul;58(7):211-4
references.pmid: 10941258
references.citation: FASEB J. 1996 Jul;10(9):940-54
references.pmid: 8801176
references.citation: Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4262-6
references.pmid: 10759547
references.citation: Cell. 2007 May 18;129(4):723-33
references.pmid: 17512406
references.citation: Biochem Biophys Res Commun. 1990 Nov 30;173(1):339-45
references.pmid: 2175182
references.citation: Biochemistry. 2007 Nov 27;46(47):13461-7
references.pmid: 17983246
references.citation: Tissue Eng Part C Methods. 2008 Dec;14(4):353-8
references.pmid: 18800876
references.citation: Oncogene. 2000 Feb 21;19(8):1038-44
references.pmid: 10713687
references.citation: J Cell Physiol. 2008 Nov;217(2):558-68
references.pmid: 18615582
references.citation: J Mammary Gland Biol Neoplasia. 2008 Sep;13(3):323-35
references.pmid: 18651209
references.citation: Cancer Res. 2006 Apr 15;66(8):4240-8
references.pmid: 16618747
references.citation: J Mammary Gland Biol Neoplasia. 1999 Jan;4(1):105-22
references.pmid: 10219910
references.citation: Am J Hematol. 2002 May;70(1):39-47
references.pmid: 11994980
references.citation: Apoptosis. 2001 Oct;6(5):377-88
references.pmid: 11483862
references.citation: Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15853-8
references.pmid: 14668450
references.citation: N Engl J Med. 1990 Sep 20;323(12):795-801
references.pmid: 2202902
references.citation: J Clin Pharm Ther. 2008 Aug;33(4):331-8
references.pmid: 18613850
references.citation: Cell. 1988 Nov 18;55(4):619-25
references.pmid: 3180222
references.citation: J Pathol. 2000 Jan;190(1):15-9
references.pmid: 10640987